This Amendment No. 10 to Schedule 13D (this Amendment) relates to the
Class A common stock, par value $0.001 per share (the Class A Common Stock), of Reata Pharmaceuticals, Inc., a Delaware corporation (the Issuer) and amends and supplements the statement on Schedule 13D originally
filed by Mr. Rose on June 6, 2016, as amended by that certain Amendment No. 1 to Schedule 13D filed on August 19, 2016, as amended by that certain Amendment No. 2 to Schedule 13D filed on December 7, 2016, as amended by
that certain Amendment No. 3 to Schedule 13D filed on January 3, 2017, as amended by that certain Amendment No. 4 to Schedule 13D filed on March 3, 2017, as amended by that certain Amendment No. 5 to Schedule 13D filed on
July 12, 2017, as amended by that certain Amendment No. 6 to Schedule 13D filed on August 2, 2017, as amended by that certain Amendment No. 7 to Schedule 13D filed on December 8, 2017, as amended by that certain Amendment
No. 8 to Schedule 13D filed on July 31, 2018, as amended by that certain Amendment No. 9 to Schedule 13D filed on November 14, 2018 (as amended, the Prior Schedule 13D). Except as otherwise specified in this
Amendment, all items left blank remain unchanged in all material respects and any items that are reported are deemed to amend and restate the corresponding items in the Prior Schedule 13D. Unless otherwise indicated, all capitalized terms used
herein but not defined herein shall have the same meanings ascribed to them in the Prior Schedule 13D.
ITEM 3. SOURCE AND AMOUNT OF FUNDS OR
OTHER CONSIDERATION.
Item 3 of the Prior Schedule 13D is hereby amended and supplemented by adding the following:
As of November 18, 2019, certain stock options previously granted to Mr. Rose pursuant to the Issuers Amended and Restated 2007
Long Term Incentive Plan (the 2007 LTIP) representing, upon their exercise, the right to acquire a total of 31,633 shares of Class B Common Stock, are exercisable within 60 days of the date hereof. These stock options were granted
to Mr. Rose, in connection with his service on the Board of Directors of the Issuer.
ITEM 4. PURPOSE OF TRANSACTION.
Item 4 of the Prior Schedule 13D is hereby amended and supplemented by adding the following:
On November 18, 2019, the Issuer reported that it had closed the sale of a total of 2,760,000 shares of its Class A Common Stock
pursuant to an underwriting agreement, resulting in a total of 27,525,410 shares of Class A Common Stock issued and outstanding. As a result of that closing, the percentage ownership of the Class A Common Stock beneficially owned by
certain of the Reporting Persons has decreased by an amount equal to or greater than 1%.
ITEM 5. INTEREST IN SECURITIES OF ISSUER.
Item 5 of the Prior Schedule 13D is hereby amended and restated as follows:
The information set forth in Item 2, Item 3 and Item 6 is hereby incorporated by reference in its entirety.
(a) (1) Mr. Rose may be deemed to beneficially own 3,207,181 shares of Class A Common Stock, representing approximately 10.8% of
the outstanding shares of Class A Common Stock.
|
(2)
|
The Survivors Trust may be deemed to beneficially own 2,757,279 shares of Class A Common Stock,
representing approximately 9.4% of the outstanding shares of Class A Common Stock.
|
|
(3)
|
Mrs. Rose may be deemed to beneficially own 2,852,941 shares of Class A Common Stock, representing
approximately 9.7% of the outstanding shares of Class A Common Stock.
|
|
(4)
|
The Rose IRA may be deemed to beneficially own 95,662 shares of Class A Common Stock, representing
approximately 0.3% of the outstanding shares of Class A Common Stock.
|
|
(5)
|
The 2001 Trust may be deemed to beneficially own 235 shares of Class A Common Stock, representing
approximately 0.001% of the outstanding shares of Class A Common Stock.
|
|
(6)
|
The 2002 Trust may be deemed to beneficially own 537 shares of Class A Common Stock, representing
approximately 0.002% of the outstanding shares of Class A Common Stock.
|
12